N/A
N=151
Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Bottom Line
View on ClinicalTrials.gov: NCT02162992 ↗Enrolled (actual)
151
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Germans Trias i Pujol Hospital
- Primary completion
- Nov 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile |
89.22; 91.41; 145.68; 146.72 | — |
| SECONDARY QT and Corrected QT Intervals |
420.74; 421.33; 8.25; 6.81 | — |
Summary
Connective tissue diseases have been related to heart conduction disorders. The anti-Ro/SSA antibodies are thought to have a pathogenic role, and they most prevalent in systemic lupus erythematous (SLE). The aim of this study is to evaluate the relationship between SLE, arrhythmias and its serologic profile.
Eligibility Criteria
Inclusion Criteria
- Patients with SLE diagnosis, according to SLE diagnostic criteria.
Exclusion Criteria
- Patients with previous cardiac diseases (ischemic heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, valvular heart disease)
- Clinical history of heart surgery or ablation procedures
- Clinical history of other conditions that affect heart conduction:
- Steinert Disease
- Lyme Disease
- Chagas Disease
- Hypothyroidism
Data sourced from ClinicalTrials.gov (NCT02162992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.